BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37022974)

  • 1. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2021-December 2022.
    Bigouette JP; Henderson E; Traoré MA; Wassilak SGF; Jorba J; Mahoney F; Bolu O; Diop OM; Burns CC
    MMWR Morb Mortal Wkly Rep; 2023 Apr; 72(14):366-371. PubMed ID: 37022974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021.
    Alleman MM; Jorba J; Henderson E; Diop OM; Shaukat S; Traoré MA; Wiesen E; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1691-1699. PubMed ID: 34882653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, July 2019-February 2020.
    Alleman MM; Jorba J; Greene SA; Diop OM; Iber J; Tallis G; Goel A; Wiesen E; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(16):489-495. PubMed ID: 32324719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria.
    Sun Y; Keskinocak P; Steimle LN; Kovacs SD; Wassilak SG
    Vaccine X; 2024 Jun; 18():100476. PubMed ID: 38617838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019.
    Jorba J; Diop OM; Iber J; Henderson E; Zhao K; Quddus A; Sutter R; Vertefeuille JF; Wenger J; Wassilak SGF; Pallansch MA; Burns CC
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(45):1024-1028. PubMed ID: 31725706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
    Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
    Diop OM; Burns CC; Sutter RW; Wassilak SG; Kew OM;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):640-6. PubMed ID: 26086635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
    Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
    Snider CJ; Boualam L; Tallis G; Takashima Y; Abeyasinghe R; Lo YR; Grabovac V; Avagyan T; Aslam SK; Eltayeb AO; Aung KD; Wang X; Shrestha A; Ante-Orozco C; Silva MWT; Lapastora-Sucaldito N; Apostol LNG; Jikal MBH; Miraj W; Lodhi F; Kim HJ; Rusli N; Thorley BR; Kaye MB; Nishimura Y; Arita M; Sani JAM; Rundi C; Feldon K
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A58-A69. PubMed ID: 35337673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017.
    Jorba J; Diop OM; Iber J; Henderson E; Sutter RW; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2017 Nov; 66(43):1185-1191. PubMed ID: 29095803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Vaccine-Derived Poliovirus Outbreaks - Democratic Republic of the Congo and Horn of Africa, 2017-2018.
    Mbaeyi C; Alleman MM; Ehrhardt D; Wiesen E; Burns CC; Liu H; Ewetola R; Seakamela L; Mdodo R; Ndoutabe M; Wenye PK; Riziki Y; Borus P; Kamugisha C; Wassilak SGF
    MMWR Morb Mortal Wkly Rep; 2019 Mar; 68(9):225-230. PubMed ID: 30845121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notes from the Field: Circulating Vaccine-Derived Poliovirus Outbreaks - Five Countries, 2014-2015.
    Morales M; Nnadi CD; Tangermann RH; Wassilak SG
    MMWR Morb Mortal Wkly Rep; 2016 Feb; 65(5):128-9. PubMed ID: 26866942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
    Voorman A; Lyons H; Bennette C; Kovacs S; Makam JK; F Vertefeuille J; Tallis G
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A85-A92. PubMed ID: 35339308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responding to a cVDPV1 outbreak in Ukraine: Implications, challenges and opportunities.
    Khetsuriani N; Perehinets I; Nitzan D; Popovic D; Moran T; Allahverdiyeva V; Huseynov S; Gavrilin E; Slobodianyk L; Izhyk O; Sukhodolska A; Hegazi S; Bulavinova K; Platov S; O'Connor P
    Vaccine; 2017 Aug; 35(36):4769-4776. PubMed ID: 28528761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
    Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
    Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021.
    Martin J; Burns CC; Jorba J; Shulman LM; Macadam A; Klapsa D; Majumdar M; Bullows J; Frolov A; Mate R; Bujaki E; Castro CJ; Bullard K; Konz J; Hawes K; Gauld J; Blake IM; Mercer LD; Kurji F; Voorman A; Diop OM; Oberste MS; Modlin J; Macklin G; Eisenhawer M; Bandyopadhyay AS; Zipursky S
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(24):786-790. PubMed ID: 35709073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
    Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
    Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.
    Darwar R; Biya O; Greene SA; Jorba J; Al Safadi M; Franka R; Wiesen E; Durry E; Pallansch MA
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A25-A34. PubMed ID: 36863925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.